Market Overview

Robbins Arroyo LLP: Insys Therapeutics, Inc. (INSY) Securities Class Action Survives Motion to Dismiss


Shareholder rights law firm Robbins
Arroyo LLP
is investigating whether certain officers and directors
of Insys Therapeutics, Inc. (NasdaqGM: INSY) breached their fiduciary
duties to shareholders. Insys, a specialty pharmaceutical company,
develops and commercializes supportive care products.

Investors filed a class action complaint against Insys for alleged
violations of the Securities Exchange Act of 1934. According to the
complaint, Insys promoted prescriptions of its drug Subsys for off-label
uses through a kickback scheme, even though the reimbursement for Subsys
was tightly regulated and limited to on-label uses. When the government
exposed and prosecuted the scheme, Insys attempted to hide its declining
financials by publicly boasting its financial health in order to inflate
its revenues and earnings. On March 15, 2017, Insys revealed that it
would need to restate its financial statements. On June 12, 2018, U.S.
District Judge Paula A. Crotty denied defendants' motion to dismiss
plaintiff's complaint, paving the way for litigation to proceed.

View this information on the law firm's Shareholder Rights Blog:

Insys Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder
information form
on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!